Westpac Banking Corp Has $3.22 Million Stake in ABIOMED, Inc. (NASDAQ:ABMD)

Share on StockTwits

Westpac Banking Corp trimmed its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 10.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,354 shares of the medical equipment provider’s stock after selling 1,418 shares during the period. Westpac Banking Corp’s holdings in ABIOMED were worth $3,218,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABMD. Geode Capital Management LLC increased its holdings in ABIOMED by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 606,848 shares of the medical equipment provider’s stock valued at $196,924,000 after purchasing an additional 32,418 shares during the period. IFM Investors Pty Ltd grew its holdings in ABIOMED by 6.8% during the 1st quarter. IFM Investors Pty Ltd now owns 2,655 shares of the medical equipment provider’s stock worth $758,000 after acquiring an additional 170 shares during the period. Brookstone Capital Management grew its holdings in ABIOMED by 25.8% during the 1st quarter. Brookstone Capital Management now owns 1,040 shares of the medical equipment provider’s stock worth $297,000 after acquiring an additional 213 shares during the period. Central Bank & Trust Co. grew its holdings in ABIOMED by 326.6% during the 1st quarter. Central Bank & Trust Co. now owns 1,011 shares of the medical equipment provider’s stock worth $289,000 after acquiring an additional 774 shares during the period. Finally, Deltec Asset Management LLC acquired a new stake in ABIOMED during the 1st quarter worth about $810,000. Institutional investors and hedge funds own 86.63% of the company’s stock.

In other ABIOMED news, COO David M. Weber sold 8,095 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $206.26, for a total transaction of $1,669,674.70. Following the completion of the transaction, the chief operating officer now owns 132,913 shares in the company, valued at $27,414,635.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.40% of the stock is owned by company insiders.

Shares of ABMD opened at $193.01 on Friday. The stock has a market cap of $8.76 billion, a PE ratio of 53.61, a price-to-earnings-growth ratio of 1.68 and a beta of 0.31. ABIOMED, Inc. has a fifty-two week low of $181.02 and a fifty-two week high of $459.75. The firm’s 50-day simple moving average is $242.10 and its two-hundred day simple moving average is $280.70.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.01. The business had revenue of $207.70 million for the quarter, compared to analysts’ expectations of $210.96 million. ABIOMED had a net margin of 32.35% and a return on equity of 19.84%. The business’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.95 earnings per share. On average, sell-side analysts forecast that ABIOMED, Inc. will post 4.3 EPS for the current fiscal year.

A number of brokerages have weighed in on ABMD. BTIG Research downgraded ABIOMED from a “buy” rating to a “neutral” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded ABIOMED from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. Guggenheim downgraded ABIOMED from a “buy” rating to a “neutral” rating in a report on Friday, August 2nd. William Blair reiterated a “buy” rating on shares of ABIOMED in a report on Friday, August 2nd. Finally, BidaskClub upgraded ABIOMED from a “strong sell” rating to a “sell” rating in a report on Wednesday, July 24th. Three research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. ABIOMED presently has an average rating of “Hold” and an average price target of $316.50.

About ABIOMED

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

See Also: What are the benefits of momentum investing?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
$1.31 EPS Expected for Microchip Technology Inc.  This Quarter
$1.31 EPS Expected for Microchip Technology Inc. This Quarter
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
-$0.63 Earnings Per Share Expected for Instructure Inc  This Quarter
-$0.63 Earnings Per Share Expected for Instructure Inc This Quarter


© 2006-2019 Ticker Report